TCT 2022 | BYPASS CTCA

Studies have shown that the use of computed tomography cardiac angiography (CTCA) prior invasive coronary angiography (ICA) in patients with prior cardiac artery bypass graft (CABG) might reduce procedural time and post procedure kidney injury. 1 out of 5 patients with ischemic cardiomyopathy and prior CABG need to be assessed with ICA within 3 years after procedure. 

TCT 2022

The aim of this single center, prospective, randomized study called BYPASS CTCA was to assess whether the use of CTCA can reduce procedural time, improve patient satisfaction and prevent procedural complication in CABG patients assessed by ICA. 

It included 688 patients. 344 were randomized to CTCA + ICA and 344 to ICA alone. Mean age was 70 and most patients were men.  

Primary end point was procedure duration, incidence of contrast induced nephropathy and patient satisfaction assessed by a score. Secondary end point included procedural complications and major cardiovascular events (MACE) at 12 months. 

As regards primary end point, the use of CTCA saw an improvement associated to the invasive study. Procedure duration was 17.38 minutes with CTCA vs 39.5 without it, with 66% relative risk reduction (p<0.001), and patient satisfaction improved 40% with the use of CTCA (p<0.001), while contrast induced nephropathy incidence was 27.9% without CTCA vs 3.4% with CTCA (92% relative risk reduction, p<0.0001). 

Read also: TCT 2022 | PROTECTED TAVR.

As regards secondary end point, the use of CTCA + ICA resulted in lower procedural complications (2.33% vs 10.82%, p<0.001) and MACE rates at 12 months (16.28 vs 29.36%, p< 0.002).

Conclusion

In patients with prior CABG undergoing invasive coronary angiogram, the use of CTCA should be considered, seeing as is shortens procedural time, improves patient satisfaction and reduces contrast induced nephropathy. In addition, the use of CTCA reduces complications rate and MACE rate at 12 months. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: A Randomized Controlled Trial Assessing The Value Of Computed Tomography Cardiac Angiography (CTCA) In Improving Patient Satisfaction And Reducing Contrast Load, Procedural Duration And Complications In Patients Who Had Previous Bypass Operation (CABG). Results from the BYPASS CTCA Trial.

Reference: Daniel A. Jones et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....